Cutting-edge immunotherapy treatment approved for another deadly cancer – Kankakee Daily Journal
|
Cutting-edge immunotherapy treatment approved for another deadly cancer
Kankakee Daily Journal The one-time infusion, known as CAR T-cell therapy, is made by Kite Pharma, which is based in Santa Monica, Calif., and recently was bought by Gilead Sciences for $11.9 billion. Kite announced Wednesday the treatment's brand name will be Yescarta and … |
